Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) Director James Arthur Bristol sold 2,595 shares of the company’s stock in a transaction dated Tuesday, February 5th. The shares were sold at an average price of $28.02, for a total transaction of $72,711.90. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.
DCPH stock traded up $0.09 during mid-day trading on Thursday, reaching $27.12. 150,937 shares of the stock traded hands, compared to its average volume of 254,413. The company has a debt-to-equity ratio of 0.06, a current ratio of 18.46 and a quick ratio of 18.46. Deciphera Pharmaceuticals Inc has a 52 week low of $18.55 and a 52 week high of $45.61. The stock has a market capitalization of $1.02 billion, a price-to-earnings ratio of -9.07 and a beta of 3.33.
Get Deciphera Pharmaceuticals alerts:Deciphera Pharmaceuticals (NASDAQ:DCPH) last announced its quarterly earnings data on Thursday, November 8th. The company reported ($0.65) EPS for the quarter, meeting the Zacks’ consensus estimate of ($0.65). Equities analysts expect that Deciphera Pharmaceuticals Inc will post -2.62 EPS for the current fiscal year.
DCPH has been the subject of a number of recent analyst reports. Leerink Swann decreased their price target on shares of Deciphera Pharmaceuticals from $28.00 to $20.00 and set an “underperform” rating for the company in a report on Friday, November 16th. BidaskClub upgraded shares of Deciphera Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, December 1st. Zacks Investment Research upgraded shares of Deciphera Pharmaceuticals from a “hold” rating to a “buy” rating and set a $27.00 price target for the company in a report on Tuesday, January 8th. Cantor Fitzgerald restated a “buy” rating and set a $53.00 price target on shares of Deciphera Pharmaceuticals in a report on Thursday, December 20th. Finally, B. Riley cut shares of Deciphera Pharmaceuticals from a “buy” rating to a “neutral” rating in a report on Tuesday, January 1st. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have given a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $42.67.
Several institutional investors and hedge funds have recently made changes to their positions in DCPH. Citadel Advisors LLC raised its position in shares of Deciphera Pharmaceuticals by 1,048.3% during the third quarter. Citadel Advisors LLC now owns 315,462 shares of the company’s stock valued at $12,215,000 after buying an additional 287,991 shares during the last quarter. Emerald Mutual Fund Advisers Trust raised its position in shares of Deciphera Pharmaceuticals by 30.3% during the third quarter. Emerald Mutual Fund Advisers Trust now owns 667,262 shares of the company’s stock valued at $25,836,000 after buying an additional 155,082 shares during the last quarter. Fosun International Ltd acquired a new position in shares of Deciphera Pharmaceuticals during the third quarter valued at about $4,958,000. Janus Henderson Group PLC raised its position in shares of Deciphera Pharmaceuticals by 21.6% during the third quarter. Janus Henderson Group PLC now owns 679,498 shares of the company’s stock valued at $26,310,000 after buying an additional 120,683 shares during the last quarter. Finally, Emerald Advisers Inc. PA raised its position in shares of Deciphera Pharmaceuticals by 19.0% during the third quarter. Emerald Advisers Inc. PA now owns 704,514 shares of the company’s stock valued at $27,279,000 after buying an additional 112,290 shares during the last quarter. 54.82% of the stock is owned by institutional investors and hedge funds.
WARNING: This news story was originally published by Ticker Report and is owned by of Ticker Report. If you are accessing this news story on another site, it was illegally copied and reposted in violation of US & international copyright and trademark law. The correct version of this news story can be accessed at https://www.tickerreport.com/banking-finance/4134207/deciphera-pharmaceuticals-inc-dcph-director-james-arthur-bristol-sells-2595-shares.html.Deciphera Pharmaceuticals Company Profile
Deciphera Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. The company's lead drug candidate is DCC-2618, which is in Phase III trial for the treatment of gastrointestinal stromal tumors; and that is in Phase I trial for treating advanced systemic mastocytosis, gliomas, and other solid tumors.
Featured Article: Net Income
No comments:
Post a Comment